Science and technology awards

DuPont Names 2021 Lavoisier and Pedersen Award Medalists

Retrieved on: 
Thursday, July 29, 2021
Scientists, Science and technology awards, Science, DuPont, Lavoisier Medal, DuPont, Wilmington, Delaware, Antoine Lavoisier

WILMINGTON, Del., July 29, 2021 /PRNewswire/ --DuPont (NYSE:DD) today announced it hasnamedsevenDuPontscientistsand engineersas recipients of thecompany's2021Lavoisier Medalfor LifetimeTechnical Achievementand theprestigiousPedersen Award Medal.

Key Points: 
  • WILMINGTON, Del., July 29, 2021 /PRNewswire/ --DuPont (NYSE:DD) today announced it hasnamedsevenDuPontscientistsand engineersas recipients of thecompany's2021Lavoisier Medalfor LifetimeTechnical Achievementand theprestigiousPedersen Award Medal.
  • The two Lavoisier Medalists areMr.MarkBarger,Technical Laureate, DuPont Water & ProtectionandDr.Peter Berg, Senior Laureate,DuPont Water & Protection.
  • Thefive Pedersen Medalists areDr.MingqiLi,Technical Laureate, DuPontElectronics & Industrial, Dr.DavidLuckey,Technical Laureate, DuPontWater & Protection,Ms.LindaNartker,Principal Investigator, DuPontElectronics & Industrial,Dr.Ed Smith,Principal Investigator, DuPontMobility & MaterialsandMr.KohtaroTakahashi,Technical Laureate, DuPontElectronics & Industrial.
  • Pedersen Medalists are selected by The DuPont Fellows, a group of the highest technical professionals in the company.

The Association of American Physicians and Surgeons (AAPS) Asks: How Do We Know the Effects of the Genetic Technology behind COVID Vaccines?

Retrieved on: 
Thursday, July 22, 2021
Awards, AAPS, Association of American Physicians and Surgeons, Jennifer Doudna, Science and technology awards, Science and technology in the United States

The Association of American Physicians and Surgeons (AAPS) states that conclusions should be based on scientific evidence, not solely on expert opinion.

Key Points: 
  • The Association of American Physicians and Surgeons (AAPS) states that conclusions should be based on scientific evidence, not solely on expert opinion.
  • Renowned genetic researcher and Nobel Prize winner Jennifer Doudna discussed both promises and pitfalls in her popular 2017 book, A Crack in Creation .
  • Currently all authorized COVID vaccines are products of genetic technology, which is poorly understood by the public.
  • The Association of American Physicians and Surgeons has represented physicians in all specialties since 1943.

Terasaki Institute for Biomedical Innovation Announces Scientific Advisory Board

Retrieved on: 
Thursday, July 8, 2021
Massachusetts Institute of Technology, Science and technology awards, Scientists, Massachusetts, Robert S. Langer, Whitehead Institute, Koch Institute for Integrative Cancer Research

LOS ANGELES, July 8, 2021 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation announces the establishment of their Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, July 8, 2021 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation announces the establishment of their Scientific Advisory Board.
  • They will provide the Institute with an external scientific perspective and invaluable scientific guidance to the Institute's researchers in their research and innovation efforts.
  • The Scientific Advisory Board provides not only deep scientific insights but also a global perspective with members coming from three continents.
  • Robert Langer Director, McGovern Institute for Brain Research, Director, Whitehead Institute for Biomedical Research, David H. Koch Institute Professor, Massachusetts Institute of Technology (MIT).

Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board

Retrieved on: 
Wednesday, May 26, 2021
Literature, Science and technology awards, Ancient Romans, Fellows of the American Association for the Advancement of Science, Bruce A. Sullenger, Ovid, Cavagnaro, Sab, Robert S. Langer

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Joy A. Cavagnaro, Ph.D., and Bruce A. Sullenger, Ph.D. to its Scientific Advisory Board.

Key Points: 
  • NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Joy A. Cavagnaro, Ph.D., and Bruce A. Sullenger, Ph.D. to its Scientific Advisory Board.
  • Ovid is building the intellectual and scientific platform to tackle the big questions in neuroscience so asto develop new medicines.
  • To that end, Ovid is deepening the expertise and strengths of our Scientific Advisory Board by the addition of key leaders in specific areas.Accordingly, I am delighted to welcome Dr. Cavagnaro and Dr. Sullenger to the SAB, said Professor Robert S. Langer, Sc.D., Chair of Ovids Scientific Advisory Board.
  • Dr. Cavagnaro has also co-authored numerous white papers, articles, and book chapters related to various aspects of preclinical safety assessment.

Cellino CEO Dr. Nabiha Saklayen Awarded Inaugural Tory Burch Fellowship at the Innovative Genomics Institute

Retrieved on: 
Thursday, May 20, 2021
Health, Technology, Other Technology, Other Science, General Health, Research, Science, Awards, Howard Hughes Medical Investigators, Tory Burch, Igi, Jennifer Doudna, Fashion, Burch, Science and technology awards, the Tory Burch Foundation, the Innovative Genomics Institute, Cellino, THE TORY BURCH FOUNDATION, THE INNOVATIVE GENOMICS INSTITUTE, CELLINO

b'Cellino , a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced that its CEO Dr. Nabiha Saklayen has been awarded the first Tory Burch Fellowship at the International Genomics Institute (IGI).\nThis press release features multimedia.

Key Points: 
  • b'Cellino , a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced that its CEO Dr. Nabiha Saklayen has been awarded the first Tory Burch Fellowship at the International Genomics Institute (IGI).\nThis press release features multimedia.
  • They face the same barriers that women entrepreneurs typically face, including limiting stereotypes and a lack of access to capital, education and networks.
  • This Fellowship program is the Tory Burch Foundation\xe2\x80\x99s first contribution to the vital issue of women in STEM and we could not be more thrilled to be partnering with brilliant, trailblazing Jennifer Doudna and the Innovative Genomics Institute,\xe2\x80\x9d said Tory Burch, CEO at Tory Burch.\n"Part of our mission at the Innovative Genomics Institute is to be the bridge from research to real-world impact,\xe2\x80\x9d said Dr. Doudna.
  • We are delighted to partner with the Tory Burch Foundation and welcome Dr. Saklayen as our first fellow.\xe2\x80\x9d\n\xe2\x80\x9cI am honored to receive the first Tory Burch Fellowship at the IGI and have Nobel Prize Laureate Dr. Jennifer Doudna and leading designer and entrepreneur Tory Burch as mentors,\xe2\x80\x9d said Nabiha Saklayen, Ph.D., CEO and Co-Founder at Cellino.

Sigilon Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

Retrieved on: 
Monday, May 10, 2021
Medicine, Science and technology awards, Branches of biology, Lemelson–MIT Prize, Robert S. Langer, Biomaterial, Fibrosis

Stock-based compensation expense increased to $0.8 million from $0.2 million for the three months ended March 31, 2021 and 2020, respectively.

Key Points: 
  • Stock-based compensation expense increased to $0.8 million from $0.2 million for the three months ended March 31, 2021 and 2020, respectively.
  • The increase in general and administrative expenses was primarily driven by $1.0 million in increased costs from operating as a public company in the first quarter of 2021.
  • The engineered cells are protected by Sigilon\xe2\x80\x99s Afibromer\xe2\x84\xa2 biomaterials matrix, which shields them from immune rejection and fibrosis.
  • Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.\nThis press release includes forward-looking statements.

Xenter, Inc. Appoints Industry Leaders Robert S. Langer, Elazer R. Edelman, David J. Bearss and Mark Stautberg to Board of Directors; Closes $12M Series A

Retrieved on: 
Friday, May 7, 2021
Mobile, Wireless, Technology, Medical devices, Cardiology, Software, Biotechnology, Internet, Hardware, Pharmaceutical, Health, Science and technology awards, Scientists, Food and Drug Administration, United States Public Health Service, Robert S. Langer, Medication, Medical device, Awards

He served as Chairman of the FDA\xe2\x80\x99s Science Board (its highest advisory board) from 1999-2002.

Key Points: 
  • He served as Chairman of the FDA\xe2\x80\x99s Science Board (its highest advisory board) from 1999-2002.
  • His graduate thesis work, under the direction of Prof. Robert Langer, defined the mathematics of regulated and controlled drug delivery systems.
  • Dr. Bearss served as Chief Scientific Officer at Montigen Pharmaceuticals and SuperGen Inc. overseeing early drug discovery and development.
  • He also served on numerous medical device company Boards, both private & public, where he mentored commercial teams to success.

InterVenn Biosciences Announces that Nobel Laureate James P. Allison, PhD, has Joined the Company’s Board of Advisors

Retrieved on: 
Thursday, April 15, 2021
Software, General Health, Pharmaceutical, Oncology, Medical devices, Technology, Hospitals, Genetics, Clinical trials, Biotechnology, FDA, Health, Science and technology awards, James P. Allison, Padmanee Sharma, Awards, Science and technology in the United States

b'InterVenn Biosciences today announced that Nobel Prize recipient, James P. Allison, has joined the company\xe2\x80\x99s Board of Advisors, effective March 9, 2021.

Key Points: 
  • b'InterVenn Biosciences today announced that Nobel Prize recipient, James P. Allison, has joined the company\xe2\x80\x99s Board of Advisors, effective March 9, 2021.
  • Dr. Padmanee Sharma, MD, PhD, Dr. Allison\xe2\x80\x99s close collaborator at MD Anderson Cancer Center, is also joining InterVenn\xe2\x80\x99s Board of Advisors.\nDr.
  • He established a new principle for cancer therapy involving the activation of the immune system to fight cancer cells.
  • For more information about InterVenn Biosciences, please visit the company\xe2\x80\x99s website .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005369/en/\n'

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

Retrieved on: 
Thursday, March 18, 2021
Science and technology awards, Scientists, Lemelson–MIT Prize, Robert S. Langer, Awards

Net Loss: Net loss was $15.2 million for the quarter ended December 31, 2020 compared to $14.7 million for the same period of 2019.

Key Points: 
  • Net Loss: Net loss was $15.2 million for the quarter ended December 31, 2020 compared to $14.7 million for the same period of 2019.
  • For the full year 2020, Sigilon reported a net loss of $54.6million, compared to a net loss of $43.9 million for the full year 2019.
  • Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform.
  • Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

OncoHost Welcomes Nobel Prize Winner to Scientific Advisory Board

Retrieved on: 
Monday, January 11, 2021
Learned societies, Science and technology awards, Nobel laureates, Israeli Jews, Aaron Ciechanover, Lasker Award, Nobel Prize, Avram Hershko

BINYAMINA, Israel, Jan. 11, 2021 /PRNewswire/ -- OncoHost , global leader in host response profiling for improved personalized cancer therapy, announced today that renowned biologist and winner of The Nobel Prize in Chemistry , Professor Aaron Ciechanover, has joined the company's scientific advisory board.

Key Points: 
  • BINYAMINA, Israel, Jan. 11, 2021 /PRNewswire/ -- OncoHost , global leader in host response profiling for improved personalized cancer therapy, announced today that renowned biologist and winner of The Nobel Prize in Chemistry , Professor Aaron Ciechanover, has joined the company's scientific advisory board.
  • His profound scientific knowledge in protein biology and fundamental discoveries in protein turnover that awarded him the 2004 Nobel Prize in Chemistry will be an invaluable contribution to our research efforts in identifying effective personalized cancer treatments," said Dr. Ofer Sharon, CEO of OncoHost.
  • Among the many accolades that Prof. Ciechanover has been awarded are the 2000 Albert Lasker Prize for Basic Medical Research, the 2003 Israel Prize for Biological Research, and the 2004 Nobel Prize in Chemistry.
  • OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy.